References

Unresolved reference

2016 · External reference

Immunological & metabolic responses to a therapeutic course of Basti in obesity

10.4103/0971-5916.162099 · 2015 · External reference

Unresolved reference

2014 · External reference

Vagus nerve stimulation in refractory epilepsy: effects on pro-and anti-inflammatory cytokines in peripheral blood

10.1159/000315530 · 2011 · External reference

Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson's disease

10.1089/ars.2014.5859 · 2014 · External reference

Parkinson disease

10.1111/ene.14108 · 2020 · External reference

Dopaminergic cell death induced by MPP+, oxidant, and specific neurotoxicants share a common molecular mechanism

10.1046/j.1471-4159.2001.00096.x · 2001 · External reference

Parkinson's disease and parkinsonism: neuropathology

10.1101/cshperspect.a009258 · 2012 · External reference

Mitochondria, oxidative damage, and inflammation in Parkinson's disease

10.1111/j.1749-6632.2003.tb07470.x · 2003 · External reference

Linking glycation and glycosylation with inflammation and mitochondrial dysfunction in parkinson's disease

10.3389/fnins.2018.00381 · 2018 · External reference

Protein quality control by molecular chaperones in neurodegeneration

10.3389/fnins.2017.00185 · 2017 · External reference

Inflammation and adaptive immunity in Parkinson's disease

10.1101/cshperspect.a009381 · 2012 · External reference

Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies

10.1093/brain/awx056 · 2017 · External reference

Regulation of striatal astrocytic receptor for advanced glycation end-products variants in an early stage of experimental Parkinson's disease

10.1111/jnc.13682 · 2016 · External reference

TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of parkinson's disease

10.1007/978-1-4419-6612-4_56 · 2011 · External reference

10.1074/jbc.m309304200

10.1074/jbc.m309304200 · 2004 · External reference

Response by Sreejit and Nagareddy to a letter regarding the article, “neutrophil-Derived S100A8/A9 amplify granulopoiesis after myocardial infarction.”

10.1161/circulationaha.120.049408 · 2020 · External reference

Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies

10.1186/s12974-018-1210-9 · 2018 · External reference

Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics, and neuroimaging

10.1515/cclm-2014-0783 · 2015 · External reference

Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease

10.1016/j.bbrc.2006.05.011 · 2006 · External reference

The predictive value of SS-16 in clinically diagnosed Parkinson's disease patients: Comparison with 99mTc-TRODAT-1 SPECT scans

10.1186/s40035-016-0062-4 · 2016 · External reference

Oxidized DJ-1 as a possible biomarker of Parkinson's disease

10.3164/jcbn.13-108 · 2014 · External reference

Plasma and urinary HPLC-ED determination of the ratio of 8-OHdG/2-dG in Parkinson's disease

2011 · External reference

Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease

10.1016/j.nbd.2008.11.011 · 2009 · External reference

Unresolved reference

2013 · External reference

10.1016/j.neulet.2009.11.065

10.1016/j.neulet.2009.11.065 · 2010 · External reference

Serum uric acid in patients with parkinson's disease and vascular parkinsonism: a cross-sectional Study

10.1159/000342483 · 2013 · External reference

A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease

2013 · External reference

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

10.1093/brain/awq008 · 2010 · External reference

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

10.1016/s1474-4422(11)70014-x · 2011 · External reference

Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity

10.1111/ene.12176 · 2014 · External reference

α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients

10.1371/journal.pone.0018513 · 2011 · External reference

CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders

10.1016/j.parkreldis.2014.01.011 · 2014 · External reference

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

10.1002/ana.22311 · 2011 · External reference

Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis

10.1002/mds.20197 · 2004 · External reference

The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in lewy body disease

10.3233/jad-2010-1289 · 2010 · External reference

miRNA-124 in immune system and immune disorders

10.3389/fimmu.2016.00406 · 2016 · External reference

Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson's disease

10.1007/s10072-010-0335-0 · 2011 · External reference

Serum and fecal markers of intestinal inflammation and intestinal barrier permeability are elevated in parkinson's disease

10.3389/fnins.2021.689723 · 2021 · External reference

10.1186/s13024-021-00427-6

10.1186/s13024-021-00427-6 · External reference

Interaction between Parkin and α-Synuclein in PARK2-Mediated parkinson's disease

10.3390/cells10020283 · 2021 · External reference

Vagus nerve as modulator of the brain-gut axis in psychiatric and inflammatory disorders

10.3389/fpsyt.2018.00044 · 2018 · External reference

The brain-gut-microbiome axis

10.1016/j.jcmgh.2018.04.003 · 2018 · External reference

The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems

2015 · External reference

The vagus nerve at the interface of the microbiota-gut-brain axis

10.3389/fnins.2018.00049 · 2018 · External reference

You may need the vagus nerve to understand the pathophysiology and to treat diseases

10.1042/cs20110299 · 2012 · External reference

Non-invasive vagus nerve stimulation improves clinical and molecular biomarkers of Parkinson's disease in patients with freezing of gait

2021 · External reference

Noninvasive vagus nerve stimulation to target gait impairment in Parkinson's disease

10.1002/mds.27664 · 2019 · External reference

Vagus nerve electrical stimulation inhibits serum levels of S100A8 protein in septic shock rats

10.3892/mmr.2016.5002 · 2016 · External reference

Vagus nerve stimulation with mild stimulation intensity exerts anti-inflammatory and neuroprotective effects in parkinson's disease model rats

2021 · External reference

Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson's disease

10.1016/j.brs.2020.06.078 · 2020 · External reference

Biological and clinical implications of comorbidities in parkinson's disease

10.3389/fnagi.2017.00394 · 2017 · External reference

Shared dysregulated pathways lead to Parkinson's disease and diabetes

10.1016/j.molmed.2013.01.002 · 2013 · External reference

Blood dendritic cell frequency declines in idiopathic parkinson's disease and is associated with motor symptom severity

10.1371/journal.pone.0065352 · 2013 · External reference

Parkinson's disease, insulin resistance and novel agents of neuroprotection

10.1093/brain/aws009 · 2013 · External reference

Differential effects of vagus nerve stimulation strategies on glycemia and pancreatic secretions

10.14814/phy2.14479 · 2020 · External reference

Major depressive disorder in Parkinson's disease: a register-based study

10.1034/j.1600-0447.2002.02229.x · 2002 · External reference

Depression and cognitive impairment in parkinson's disease: a role for inflammation and immunomodulation?

10.1159/000356531 · 2014 · External reference

Vagus nerve stimulation for treatment-resistant depression: a vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial randomized

2005 · External reference

Inflammasomes: mechanism of action, role in disease, and therapeutics

10.1038/nm.3893 · 2015 · External reference

Oxidative stress, eryptosis, and anemia: a pivotal mechanistic nexus in systemic diseases

10.1111/febs.14606 · 2019 · External reference

Unresolved reference

2014 · External reference

Anemia of inflammation

10.1016/j.hoc.2014.04.005 · 2014 · External reference

Serum Iron levels and the risk of parkinson disease: a mendelian randomization study

10.1371/annotation/c4d81646-0c0e-4a3e-9425-b220bae2d8b6 · 2013 · External reference

Meta-analysis of the relationship between Parkinson's disease and melanoma

10.1212/wnl.0b013e31821e554e · 2011 · External reference

Parkinson's disease: biomarkers, treatment, and risk factors

10.3389/fnins.2018.00612 · 2018 · External reference

Can the vagus nerve serve as a biomarker for Vata dosha activity?

10.1016/j.jaim.2019.04.003 · 2019 · External reference

Management of Parkinson's disease in Ayurveda: medicinal plants and adjuvant measures

10.1016/j.jep.2016.08.020 · 2017 · External reference

The microbiome in health and disease from the perspective of modern medicine and Ayurveda

2020 · External reference

An experimental study to evaluate the pharmacokinetic aspect of Lekhana Basti (Emaciating/Desiccating Medicated Enema)

2011 · External reference

Efficacy of Āyurvedic treatment using Pañcakarma combined with balance exercises for disability and balance in progressive supranuclear palsy

10.4103/0257-7941.113793 · 2012 · External reference

A case study on the Ayurvedic management of cerebral palsy

10.4103/0257-7941.157163 · 2015 · External reference

Clinical study on the efficacy of Rajayapana Basti and Baladi Yoga in motor disabilities of cerebral palsy in children

10.4103/0974-8520.153748 · 2014 · External reference

Effect of Anuvasana Basti with Ksheerabala Taila in Sandhigata Vata (Osteoarthritis)

10.4103/0974-8520.146225 · 2014 · External reference

Ayurvedic management of chronic constipation in Hirschsprung disease - a case study

10.1016/j.jaim.2017.11.004 · 2018 · External reference

Efficacy of Virechana and Basti Karma with Shamana therapy in the management of essential hypertension: a comparative study

10.4103/0974-8520.115455 · 2013 · External reference

Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson's Disease

10.3390/cells9020376 · 2020 · External reference

Intestinal lipid–derived signals that sense dietary fat

10.1172/jci76302 · 2015 · External reference

Basti: does the equipment and method of administration matter?

10.4103/0975-9476.109543 · 2013 · External reference

Microbial metabolites and the vagal afferent pathway in the control of food intake

2021 · External reference

Gut sensory neurons as regulators of neuro-immune-microbial interactions: from molecular mechanisms to precision therapy for IBD/IBS

10.1186/s12974-025-03500-9 · 2025 · External reference

Internal senses of the vagus nerve

10.1016/j.neuron.2021.12.020 · 2022 · External reference

Sensory neurons that detect stretch and nutrients in the digestive System

10.1016/j.cell.2016.05.011 · 2016 · External reference

Rectal distention-induced colonic net water secretion in rats involves tachykinins, capsaicin sensory, and vagus nerves

10.1016/s0016-5085(97)70041-6 · 1997 · External reference

Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes

10.1007/s00592-023-02088-x · 2023 · External reference

Vagal sensory neurons and gut-brain signalling

10.1016/j.conb.2020.03.006 · 2020 · External reference

Role of Gut Microbiota in neuroendocrine regulation of carbohydrate and lipid metabolism via the microbiota-gut-brain-liver axis

10.3390/microorganisms8040527 · 2020 · External reference

Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease

10.1016/s0022-510x(00)00329-4 · 2000 · External reference

Self-administration of right vagus nerve stimulation activates midbrain dopaminergic nuclei

10.3389/fnins.2021.782786 · 2021 · External reference

Unresolved reference

2015 · External reference

Managing kampavata (Parkinson's disease) through ayurveda: an experience

2019 · External reference

Reduced risk of parkinson disease in patients with rheumatoid arthritis: a nationwide population-based Study

10.1016/j.mayocp.2016.06.023 · 2016 · External reference

Effect of Kshara Basti and nirgundi Ghana Vati on amavata (Rheumatoid arthritis)

10.4103/0974-8520.100310 · 2012 · External reference

Clinical efficacy of Panchamuladi Kaala Basti (enema) in the management of Amavata (Rheumatoid Arthritis)

10.4103/0974-8520.85737 · 2011 · External reference

Neurostimulation for neurogenic bowel dysfunction

10.1155/2013/563294 · 2013 · External reference

Integrated network pharmacology, molecular docking and animal experiment to explore the efficacy and potential mechanism of baiyu decoction against ulcerative colitis by enema

10.2147/dddt.s432268 · 2023 · External reference

Vagus nerve stimulation and the cardiovascular System

10.1101/cshperspect.a034173 · 2020 · External reference

Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn's disease and irritable bowel syndrome

10.1371/journal.pone.0105328 · 2014 · External reference

[11C]PIB binding in Parkinson's disease dementia

10.1016/j.neuroimage.2007.09.072 · 2008 · External reference

Vagus nerve stimulation for treatment of inflammation: systematic review of animal models and clinical studies

10.15424/bioelectronmed.2016.00005 · 2016 · External reference